Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754266 | 0.85 | KMT2A (0.45) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL17676813 | 0.81 | ELANE (0.61) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL19431469 | 0.79 | KMT2A (0.50) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL24196735 | 0.78 | ELANE (0.46) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL26038495 | 0.77 | SMN1; SMN2 (0.59) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL19431512 | 0.77 | KMT2A (0.59) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL18879707 | 0.77 | KMT2A (0.59) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL19431510 | 0.77 | KMT2A (0.59) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL19431470 | 0.77 | SMN1; SMN2 (0.59) | KMT2AHTTSMN1; SMN2TDP1ELANE | |
| SCHEMBL19431397 | 0.77 | ELANE (0.54) | KMT2AHTTSMN1; SMN2TDP1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | DIC CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | DIC CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | RCC1, LPXN, SMC4 | KMT2A 2308/4885HTT 3427/4885SMN1; SMN2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.